Smith & Nephew plc (LON:SN)
1,091.00
-5.00 (-0.46%)
Aug 17, 2026, 3:40 PM GMT
Smith & Nephew Revenue
Smith & Nephew had revenue of $3.10B USD in the half year ending June 27, 2026, with 9.55% growth. This brings the company's revenue in the last twelve months to $6.30B, up 5.99% year-over-year. In the year 2025, Smith & Nephew had annual revenue of $6.16B with 6.09% growth.
Revenue (ttm)
$6.30B
Revenue Growth
+5.99%
P/S Ratio
1.93
Revenue / Employee
$370.59K
Employees
17,000
Market Cap
9.22B GBP
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.16B | 354.00M | 6.09% |
| Dec 31, 2024 | 5.81B | 261.00M | 4.70% |
| Dec 31, 2023 | 5.55B | 334.00M | 6.40% |
| Dec 31, 2022 | 5.22B | 3.00M | 0.06% |
| Dec 31, 2021 | 5.21B | 652.00M | 14.30% |
| Dec 31, 2020 | 4.56B | -578.00M | -11.25% |
| Dec 31, 2019 | 5.14B | 234.00M | 4.77% |
| Dec 31, 2018 | 4.90B | 139.00M | 2.92% |
| Dec 31, 2017 | 4.77B | 96.00M | 2.06% |
| Dec 31, 2016 | 4.67B | 35.00M | 0.76% |
| Dec 31, 2015 | 4.63B | 17.00M | 0.37% |
| Dec 31, 2014 | 4.62B | 266.00M | 6.11% |
| Dec 31, 2013 | 4.35B | 214.00M | 5.17% |
| Dec 31, 2012 | 4.14B | -133.00M | -3.11% |
| Dec 31, 2011 | 4.27B | 308.00M | 7.77% |
| Dec 31, 2010 | 3.96B | 190.00M | 5.04% |
| Dec 31, 2009 | 3.77B | -29.00M | -0.76% |
| Dec 31, 2008 | 3.80B | 432.00M | 12.82% |
| Dec 31, 2007 | 3.37B | 590.00M | 21.23% |
| Dec 31, 2006 | 2.78B | 227.00M | 8.89% |
| Dec 31, 2005 | 2.55B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 46.25B |
| GSK plc | 33.20B |
| Haleon | 11.15B |
| Hikma Pharmaceuticals | 2.58B |
| Convatec Group | 1.88B |
| Spire Healthcare Group | 1.58B |
| CVS Group | 692.80M |
| Genus | 672.00M |
Smith & Nephew News
- 2 hours ago - Smith+Nephew's new FLOW FLEXTEND™ COBLATION™ Wand improves access¹* and resection efficiency²** for complex hip procedures vs. fixed-angle options - GlobeNewsWire
- 8 days ago - Smith & Nephew SNATS Q2 Earnings Call Highlights - MarketBeat
- 10 days ago - Smith & Nephew price target lowered to 1,250 GBp from 1,350 GBp at RBC Capital - TheFly
- 10 days ago - Smith & Nephew price target lowered to 1,250 GBp at Deutsche Bank - TheFly
- 11 days ago - Smith & Nephew downgraded to Neutral from Overweight at JPMorgan - TheFly
- 11 days ago - Smith & Nephew price target lowered to 1,304 GBp at Morgan Stanley - TheFly
- 11 days ago - Smith+Nephew celebrates mobility, recovery and football's greatest traditions during Pro Football Hall of Fame Enshrinement Week - GlobeNewsWire
- 12 days ago - Smith & Nephew downgraded to Underweight from Equal Weight at Barclays - TheFly